Filtered By:
Drug: SGLT2 Inhibitors
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 230 results found since Jan 2013.
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors
N Z Med J. 2022 Aug 19;135(1560):99-104.ABSTRACTThe sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout. Patients with or without diabetes who have a history of heart failure, including those with a preserved left ventricular ejection fraction and patients with ch...
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Chok G Chan Ralph Stewart Source Type: research
Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
Conclusions/interpretationIn people with diabetes, GLP1RA use was associated with significantly reduced risks of MALE compared with SGLT2i within the first 2 years after initiation, especially among people with diabetic neuropathy.Graphical abstract
Source: Diabetologia - August 9, 2022 Category: Endocrinology Source Type: research
Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database
ConclusionsTreatment with SGLT2 inhibitors or GLP-1 receptor agonists might reduce non-fatal stroke/TIA in persons with newly diagnosed type 2 diabetes.
Source: Acta Diabetologica - August 6, 2022 Category: Endocrinology Source Type: research
Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies
ConclusionOS presented significant benefits of SGLT2 inhibitors both on primary and secondary preventions of MACE, MI, stroke, ACM, CVM, and HHF; RCTs did not. Given the spectrum of T2D patient characteristics and the strength of overall evidence, our review underscored the importance of constant integration of all available information and critical interpretation of all inconsistencies to optimize evidence-based diabetes care.
Source: European Journal of Clinical Pharmacology - July 27, 2022 Category: Drugs & Pharmacology Source Type: research
Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to lower cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risks. Here, we aimed to evaluate the effect of SGLT2 inhibitors on major adverse cardiovascular events (MACE), a composite of cardiovascular mortality, myocardial infarction, or ischemic stroke and hospitalization for heart failure in patients with T2DM and atrial fibrillation (AF). Using the Korean National Health Insurance Service database, we identified 40,268 patients with T2DM and AF who were newly prescribed oral hypoglycemic drugs ...
Source: The American Journal of Cardiology - July 7, 2022 Category: Cardiology Authors: Chang Hee Kwon, Ye-Jee Kim, Min-Ju Kim, Myung-Jin Cha, Min Soo Cho, Gi-Byoung Nam, Kee-Joon Choi, Jun Kim Source Type: research
Cardiodiabetology: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks
Can J Physiol Pharmacol. 2022 Jun 30. doi: 10.1139/cjpp-2022-0065. Online ahead of print.ABSTRACTGlobally, nearly 500 million adults currently have diabetes, which is expected to increase to approximately 700 million by 2040. Cardiovascular diseases (CVD), including coronary heart disease, stroke, heart failure, and peripheral arterial disease, are the principal causes of death in persons with diabetes. Key to the prevention of CVD is optimization of associated risk factors. However, few persons with diabetes are at recommended targets for key CVD risk factors including LDL-cholesterol, blood pressure, HbA1c, nonsmoking st...
Source: Canadian Journal of Physiology and Pharmacology - June 30, 2022 Category: Drugs & Pharmacology Authors: Nathan D Wong Source Type: research
